Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SUV39H2 | Q9H5I1 | 4/20 | 0.40 |
| ▸ | EGFR | P00533 | 6/20 | 0.39 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.38 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.38 |
| ▸ | KDR | P35968 | 1/20 | 0.38 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.38 |
| ▸ | CFTR | P13569 | 1/20 | 0.38 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.38 |
| ▸ | IDO1 | P14902 | 1/20 | 0.37 |
| ▸ | AXL | P30530 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL463764 | 0.89 | AXL (0.38) | SUV39H2EGFRFGFR3ATMERBB2 | |
| SCHEMBL10266876 | 0.85 | MAPT (0.38) | SUV39H2EGFRFGFR3ATMERBB2 | |
| SCHEMBL463785 | 0.85 | KDR (0.40) | EGFRERBB2KDREPHB4MKNK2 | |
| SCHEMBL415816 | 0.76 | RET (0.47) | EGFRFGFR3ERBB2KDREPHB4 | |
| SCHEMBL16520531 | 0.72 | CA12 (0.50) | SUV39H2IDO1GAA | |
| SCHEMBL15486411 | 0.71 | ALDH1A1 (0.64) | ALDH1A1 | |
| SCHEMBL7449161 | 0.71 | CA12 (0.50) | ATMIDO1ALDH1A1GAA | |
| SCHEMBL21601499 | 0.71 | IDO1 (0.52) | IDO1ALDH1A1 | |
| SCHEMBL414296 | 0.70 | EGFR (0.42) | EGFRFGFR3KDREPHB4 | |
| SCHEMBL10258573 | 0.69 | FGFR3 (0.41) | EGFRFGFR3ERBB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8394955-B2 | 2,4 (4,6) pyrimidine derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 2013-03-12 | — | — | US | disclosed |
| US-8148388-B2 | 2,4 (4,6) pyrimidine derivatives | JANSSEN PHARMACEUTICA, N.V. (BE) | 2012-04-03 | — | — | US | disclosed |
| US-8148388-B2 | 2,4 (4,6) pyrimidine derivatives | JANSSEN PHARMACEUTICA, N.V. (BE) | 2012-04-03 | — | — | US | disclosed |
| US-20120065395-A1 | 2,4 (4,6) PYRIMIDINE DERIVATIVES | FREYNE EDDY JEAN EDGARD (BE) | 2012-03-15 | — | — | US | disclosed |
| US-20100160310-A1 | 2,4 (4,6) PYRIMIDINE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-06-24 | — | — | US | disclosed |
| US-20100160310-A1 | 2,4 (4,6) PYRIMIDINE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065395-A1 | 2,4 (4,6) PYRIMIDINE DERIVATIVES | NR0B1, NR1H3, NCOA3 | SUV39H2 3776/4885EGFR 1090/4885FGFR3 536/4885 |
| US-20100160310-A1 | 2,4 (4,6) PYRIMIDINE DERIVATIVES | NR1H3, NR1H2, NR0B1 | SUV39H2 3963/4885EGFR 1611/4885FGFR3 639/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.